A wearable cardioverter-defibrillator vest as a diagnostic  and therapeutic tool after COVID-19

Chyży, Tomasz; Małecka, Barbara; Bednarek, Jacek; Mielnik, Małgorzata; Dębski, Maciej; Miszalski−Jamka, Tomasz; Boczar, Krzysztof; Lelakowski, Jacek; Ząbek, Andrzej

doi:10.33963/kp.a2023.0128

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…WEARIT-II and WEARIT-France are two big registries that show that WCD therapy is effective and safe in selected patients with a transient increased risk of SCD [5,6]. Apart from SCD protection, WCD provides also permanent telemetric monitoring which in several situations may allow for greater insight into patients' disease [7,8]. We aim to present a Polish single-center experience with WCD.…”

Section: Introductionmentioning

confidence: 99%

Wearable cardioverter-defibrillator in daily clinical practice: A single-centre experience

Wojtaszczyk,

Kaczmarek,

Urbanek

et al. 2024

Pol Heart J

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Wearable cardioverter-defibrillator in daily clinical practice: A single-centre experience

Wojtaszczyk,

Kaczmarek,

Urbanek

et al. 2024

Pol Heart J

View full text Add to dashboard Cite

COVID-19 and Cardiac Arrhythmias: Lesson Learned and Dilemmas

Blasi,

Vicenzi,

De Ponti

2024

JCM

View full text Add to dashboard Cite

Over the last few years, COVID-19 has attracted medical attention both in terms of healthcare system reorganization and research. Among the different cardiovascular complications of the SARS-CoV-2 infection, cardiac arrhythmias represent an important clinical manifestation requiring proper therapy both in the acute and post-acute phase. The multiparametric in-hospital monitoring of COVID-19 patients frequently detects new-onset or recurrent cardiac arrhythmias. As many patients are monitored remotely from cardiology departments, this setting calls for proper arrhythmia interpretation and management, especially in critically ill patients in the intensive care unit. From this perspective, the possible pathophysiologic mechanisms and the main clinical manifestations of brady- and tachyarrhythmias in COVID-19 patients are briefly presented. The progressively increasing body of evidence on pathophysiology helps to identify the reversible causes of arrhythmias, better clarify the setting in which they occur, and establish their impact on prognosis, which are of paramount importance to orient decision making. Despite the accumulating knowledge on this disease, some dilemmas in the management of these patients may remain, such as the need to implant in the acute or post-acute phase a permanent pacemaker or cardioverter/defibrillation in patients presenting with brady- or tachyarrhythmias and lifelong oral anticoagulation in new-onset atrial fibrillation detected during SARS-CoV-2 infection.

show abstract

A wearable cardioverter-defibrillator vest as a diagnostic and therapeutic tool after COVID-19

Cited by 2 publications

References 4 publications

Wearable cardioverter-defibrillator in daily clinical practice: A single-centre experience

Wearable cardioverter-defibrillator in daily clinical practice: A single-centre experience

COVID-19 and Cardiac Arrhythmias: Lesson Learned and Dilemmas

Contact Info

Product

Resources

About